Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update
February 22 2024 - 4:01PM
Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused
biopharmaceutical company, today announced it will report its
fourth quarter and full year 2023 financial and operating results
after the close of U.S. financial markets on Thursday, February 29,
2024.
Conference Call/Webcast Information:
Date: |
|
Thursday, February 29, 2024 |
Time: |
|
4:30 pm Eastern Time (1:30 pm Pacific Time) |
Dial-In: |
|
(800) 715-9871 or (646) 307-1963 for international callers |
Conference ID: |
|
9376408 |
A live audio webcast will be available on the
“Investors” section of Xenon's website and posted for replay
following the event. The above listed dates and times are subject
to change.
About Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals (NASDAQ:XENE) is a
clinical stage biopharmaceutical company committed to developing
innovative therapeutics to improve the lives of patients with
neurological disorders. We are advancing a novel product pipeline
of neurology therapies to address areas of high unmet medical need.
For more information, please visit www.xenon-pharma.com.
“Xenon” and the Xenon logo are registered
trademarks or trademarks of Xenon Pharmaceuticals Inc. in various
jurisdictions. All other trademarks belong to their respective
owner.
Investor/Media Contact:Jodi RegtsXenon
Pharmaceuticals Inc.Phone: 604.484.3353Email:
investors@xenon-pharma.com
Xenon Pharmaceuticals (NASDAQ:XENE)
Historical Stock Chart
From Apr 2024 to May 2024
Xenon Pharmaceuticals (NASDAQ:XENE)
Historical Stock Chart
From May 2023 to May 2024